Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cellectis Romainvil (CMVLF)

Cellectis Romainvil (CMVLF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.1600 +6.06%
on 07/24/20
17.7200 -3.27%
on 07/08/20
-0.3200 (-1.83%)
since 07/01/20
3-Month
14.6000 +17.40%
on 05/14/20
17.8000 -3.71%
on 06/22/20
+2.5400 (+17.40%)
since 04/27/20
52-Week
9.1500 +87.32%
on 10/10/19
19.0000 -9.79%
on 12/18/19
+4.0800 (+31.24%)
since 08/05/19

Most Recent Stories

More News
Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2020

-- Enrollment ongoing in Phase 1 dose-escalation trial BALLI-01 in r/r B-ALL patients

CMVLF : 17.1400 (-0.98%)
CLLS : 17.49 (+3.43%)
Cellectis to Hold Second Quarter 2020 Earnings Call on Thursday, August 6, 2020 at 7:30AM EDT

Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it...

CMVLF : 17.1400 (-0.98%)
CLLS : 17.49 (+3.43%)
Cellectis Appoints Biopharma Veteran Steve Doares, Ph.D., as Senior Vice President of US Manufacturing

Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that...

CMVLF : 17.1400 (-0.98%)
CLLS : 17.49 (+3.43%)
Worldwide CRISPR Market to 2028 - Key Drivers, Restraints, Opportunities and Challenges

, /PRNewswire/ -- The report has been added to offering.

CMVLF : 17.1400 (-0.98%)
DCYHY : 18.5200 (-15.93%)
EDIT : 34.71 (-5.78%)
MKKGY : 26.7200 (-0.48%)
Cellectis Published Streamlined Manufacturing Method to Generate Ultrapure Allogeneic CAR T-Cell Therapies

Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced the publication of a new...

CMVLF : 17.1400 (-0.98%)
CLLS : 17.49 (+3.43%)
Insights on the CRISPR Global Industry to 2028 - Featuring Applied Stemcell, Caribou Biosciences & Cellectis Among Others

The "Global CRISPR Market 2019-2028" report has been added to ResearchAndMarkets.com's offering.

CMVLF : 17.1400 (-0.98%)
Cellectis Appoints Biopharma Veteran Leopold Bertea as Senior Vice President of Technical Operations - Europe

Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced the...

CMVLF : 17.1400 (-0.98%)
NVS : 82.91 (-0.60%)
CLLS : 17.49 (+3.43%)
Cellectis' Annual Shareholders' General Meeting to be Held on June 29, 2020

Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS).

CMVLF : 17.1400 (-0.98%)
CLLS : 17.49 (+3.43%)
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2020

-- Proprietary allogeneic CAR T-cell programs on track in Phase 1 dose escalation trials; AMELI-01 in r/r AML patients, BALLI-01 in r/r B-ALL patients and MELANI-01 in r/r MM patients

CELGZ : 0.47 (+2.15%)
CMVLF : 17.1400 (-0.98%)
CLLS : 17.49 (+3.43%)
Cellectis to Hold First Quarter 2020 Earnings Call on Thursday, May 7, 2020 at 7:30 AM EDT

Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it...

CMVLF : 17.1400 (-0.98%)
CLLS : 17.49 (+3.43%)
Trade CMVLF with:

Key Turning Points

2nd Resistance Point 17.2467
1st Resistance Point 17.1933
Last Price 17.1400
1st Support Level 17.1133
2nd Support Level 17.0867

See More

52-Week High 19.0000
Last Price 17.1400
Fibonacci 61.8% 15.2373
Fibonacci 50% 14.0750
Fibonacci 38.2% 12.9127
52-Week Low 9.1500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar